Outcomes of maintenance Treatment using lenalidomide or Bortezomib in Multiple Myeloma patients post Autologous Stem Cell Transplantation

Abstract

lthough studies have illustrated a benefit in both progression-free survival (PFS) and overall survival (OS) conferred by the use of ASCT, almost all patients eventually relapse after transplantation. Because of this high rate of relapse as well as the observed correlation between the depth of response achieved and overall outcome, several groups have investigated the role of maintenance therapy after ASCT to achieve a durable remission and delay disease progression. Although many studies evaluating the role of maintenance therapy indicate a clear PFS advantage, the benefit to OS remains unclear. We conducted this study to assess the results of maintenance treatment with lenalidomide or bortezomib in multiple myeloma post autologous stem cell transplantation Our results showed that; This study revealed that, the highest survival rate at 1 year was (98.6%). Then at 3 years was (74.1%) and finally at 5 years was (18.7%). The highest PFS was at 1 year as reported in (78.4%) of cases, then at 2 years in (36.2%). As regard overall survival rate (OSR), patients received maintenance treatment was significantly better than patients who did not receive maintenance treatment. And also patients who received Lenalidomide ware significantly better than patients who received Bortezomib (p=0.005). As the median of Lenalidomide was 58 months, Bortezomib was 48 months and No maintenance was 28 months